Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems

دسته بندي : مباحث رشته ها » داروسازی
We certainly hope that this book will encourage regulatory authorities to develop new regulatory processes for independent review and use of excipients. The availability of independent review will encourage innovation and development of commercially viable new excipients. Ultimately, all this should help quickly develop lifesaving drug delivery systems benefiting humans.
 Ashok Katdare Mahesh V. Chaubal
دسته بندی: مباحث رشته ها » داروسازی

تعداد مشاهده: 4005 مشاهده

فرمت فایل دانلودی:.pdf

فرمت فایل اصلی: .pdf

تعداد صفحات: 441

حجم فایل:4,396 کیلوبایت

 قیمت: 18,000 تومان
پس از پرداخت، لینک دانلود فایل برای شما نشان داده می شود.   پرداخت و دریافت فایل
  • راهنمای استفاده:
    Preface To facilitate the development of novel drug delivery systems and biotechnologyderived drugs, the need for new excipients continues to increase. This book Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems serves as a comprehensive source to improve understanding of excipients and forge new avenues to promote independent regulatory review and development of novel excipients. In addition, this book presents in-depth information on various aspects of excipient development, safety/toxicology testing, regulatory processes, quality, manufacturability, and the utility of excipients for various drug delivery systems. We have relied on numerous experts and thought leaders from all over the world who have shared their expertise and time to prepare the chapters included in this book. Each chapter also provides a wealth of useful references that should prove to be invaluable for the reader. This book is intended for formulation scientists, analytical scientists and engineers, regulatory and compendia personnel, procurement personnel, preclinical scientists, excipient manufacturers, quality control and assurance personnel, and distributors. What makes this book so timely? In recent years, an awareness and understanding of excipients has increased based upon several important factors. First, as pharmaceutically active ingredients continue to become more ‘‘potent,’’ the effective doses have become smaller. As a result, excipients now often constitute the major portion of many pharmaceutical dosage forms and as such can have profound impact on the reproducibility of manufacture and overall quality of the dosage forms. Second, regulatory authorities, especially the U.S. Food and Drug Administration, have clearly set an expectation that quality should be built in drug products from the beginning of development and manufacture rather than simply testing quality of the finished product (quality for 21st century initiative). This stance has forced the industry and academia to develop a thorough understanding of the functionalities and modalities of excipients, as well as to develop and adopt testing methodologies from other industries to refine the characterization of excipients. Also, increased use of process analytical technologies has helped excipient manufacturers and users to develop improved in-process controls and better-controlled manufacturing processes. These efforts should enhance building quality in the manufacture of drug products.

  • محتوای فایل دانلودی:
    Excipients: Background/Introduction
    Lokesh Bhattacharyya, Stefan Schuber, Catherine Sheehan,
    and Roger William
    Department of Standards Development, United States Pharmacopeia,
    Rockville, Maryland, U.S.A.
    Almost all therapeutic products, including therapeutic products for human and
    veterinary use, include excipients—indeed, the total amount of excipients frequently
    used is greater than the amount of the active drug substance(s) in a dosage form. As
    with drug substances, excipients are derived from natural sources or are synthesized
    either chemically or by other means. They range from simple, usually highly characterized,
    organic, or inorganic molecules to highly complex materials that are difficult
    to fully characterize.
    In earlier days, excipients were considered inactive ingredients. Over time,
    pharmaceutical scientists learned that excipients are not inactive and frequently have
    substantial impact on the manufacture and quality, safety, and efficacy of the drug
    substance(s) in a dosage form. Further, variability in the performance of an excipient—both
    batch to batch within a single manufacturer as well as between batches
    from different manufacturers—came to be understood as a key determinant of
    dosage form performance. Excipients are now known to have defined functional
    roles in pharmaceutical dosage forms. These include (i) modulating solubility and
    bioavailability of the active ingredient(s); (ii) enhancing stability of the active ingredient(s)
    in finished dosage forms; (iii) helping active ingredients maintain a preferred
    polymorphic form or conformation; (iv) maintaining pH and osmolarity of liquid
    formulations; (v) acting as antioxidants, emulsifying agents, aerosol propellants,
    tablet binders, and tablet disintegrants; (vi) preventing aggregation or dissociation;
    and (vii) modulating the immunogenic response of active ingredients (e.g., adjuvants)
    and many others. United States Pharmacopeia 28–National Formulary 23 lists
    40 functional categories of excipients for pharmaceuticals, and many more are
    expected as new—and usually increasingly complex—drug-delivery systems emerge
    and evolve. Approximately 800 excipients are currently used in the marketed pharmaceutical
    products in the United States. This number is also expected to grow with
    new therapeutic categories, such as gene therapy and cell therapy, and new drugdelivery